Merck & Co., Inc. (MRK)
| Market Cap | 211.59B |
| Revenue (ttm) | 63.62B |
| Net Income (ttm) | 16.41B |
| Shares Out | 2.50B |
| EPS (ttm) | 6.49 |
| PE Ratio | 13.06 |
| Forward PE | 9.25 |
| Dividend | $3.24 (3.82%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 13,230,861 |
| Open | 83.79 |
| Previous Close | 84.05 |
| Day's Range | 83.25 - 85.27 |
| 52-Week Range | 73.31 - 120.30 |
| Beta | 0.38 |
| Analysts | Buy |
| Price Target | 108.54 (+28.13%) |
| Earnings Date | Oct 30, 2025 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $108.54, which is an increase of 28.13% from the latest price.
News
September Dogs Of The Dow Unleash One Ideal 'Safer' DiviDog
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are well-covered. Analyst forecasts suggest top Dow Dogs could de...
Merck & Co., Inc. (MRK) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Merck & Co., Inc. (NYSE:MRK) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 11:50 AM EDT Company Participants Eliav Barr - Chief Medical Officer & Head of Global Clinical Develo...
Biocytogen Enters into Agreement with Merck to Advance Antibody-Conjugated Lipid-Based Delivery Solutions
BEIJING--(BUSINESS WIRE)-- #AntibodyDrugDiscovery--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of ...
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Merck Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the appointment of David Weinreich, MD, MBA, as Global Head of R&D and Chief Medical Officer for i...
Merck's cholesterol drug meets main goal in late-stage trial
Drugmaker Merck's oral drug met the main goal of reducing bad cholesterol in a late-stage trial, it said on Tuesday, marking a second win for the drug since June.
Merck's Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C in Phase 3.
Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference.
Top 10 High-Yield Dividend Stocks For September 2025
My watchlist outperformed SPY and VYM since July 1st, offering higher yield and competitive total returns, despite trailing benchmarks year-to-date. The strategy focuses on high-quality, attractively ...
Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides New Results for Vericiguat in Patients with Chronic Heart Failure and Reduced Ejection Fraction. Results presented at ESC 2025.
Merck: Buy the Next Dip Despite Short-Term Pressures
Merck's Q2 2025 results highlight strong growth in Keytruda and Animal Health, while its bullish chart pattern and low valuation make it a compelling long-term buy.
Merck to Participate in the 2025 Wells Fargo Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the 2025 Wells Fargo Healthcare Conference.
Calls of the Day: Micron, DoorDash, Amer Sports, Amgen, Merck and Costco
The Investment Committee debate the latest Calls of the Day.
HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--HERTHENA-Breast04 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic HR+/HER2- Breast Cancer.
Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that new clinical trial and outcomes research data will be presented at the European S...
Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced r...
Merck: Shares Bucking The Gardasil Problem, Hiking My Price Target
I reiterate my buy rating on Merck, citing its attractive valuation and improving technicals despite sector headwinds. Merck's recent earnings beat was driven by strong oncology and cardiovascular por...
Merck: Buy The Weakness
Merck trades at a single-digit P/E, reflecting underperformance but strong financials and a robust dividend yield near 3.9%. Keytruda's ongoing success and expanded indications drive near-term results...
10 Undervalued Dividend Growth Stocks: August 2025
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the top ten stocks for consideration. I use two valuation screens, one based on my fair value estimate, and anoth...
KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) ...
August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys
Verizon is the only Dow stock currently meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are supported by free cash flow. Analyst forecasts suggest top Dow...
Stock Picks From Seeking Alpha's July 2025 New Analysts
In July, Seeking Alpha welcomed 44 new analysts. This article introduces them and showcases some of their top picks. Analysts provided ratings from Strong Sell to Strong Buy, with detailed justificati...
Income Strategy: I'm Buying 2 Elite Mispriced Dividends
In the current tech-heavy market, I explore two compelling value stocks with strong yields and trade at deep discounts to historical valuations. Both have competitive advantages and strong histories o...
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8.5% (August 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...